Evidence map›Paper›PMID 23787722›Full record

Trial reportEuropean journal of heart failure2013

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.

Gerasimos Filippatos, Dimitrios Farmakis, Josep Comin Colet, Kenneth Dickstein, Thomas F Lüscher, Ronnie Willenheimer, John Parissis, Giedrius Gaudesius, Claudio Mori, Barbara von Eisenhart Rothe and 4 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 8 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 8 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Intravenous iron therapy for non-anaemic, iron-deficient adults.The Cochrane database of systematic reviews · 2019
    Pooled it
  7. Iron therapy in anaemic adults without chronic kidney disease.The Cochrane database of systematic reviews · 2014
    Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 9 countries.

Gerasimos FilippatosAthens University Hospital Attikon, Athens, Greece.
Dimitrios Farmakis
Josep Comin Colet
Kenneth Dickstein
Thomas F Lüscher
Ronnie Willenheimer
John Parissis
Giedrius Gaudesius
Claudio Mori
Barbara von Eisenhart Rothe
Nicola Greenlaw
Ian Ford
Piotr Ponikowski
Stefan D Anker
University General Hospital Attikon · GRVifor Pharma (Switzerland) · CHMalmö University · SEStavanger University Hospital · NOThe Robertson Trust · GBUniversitat Autònoma de Barcelona · ESUniversity Hospital of Zurich · CHUniversity of Glasgow · GBVita-Salute San Raffaele University · ITWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTherapy with i.v. iron in patients with chronic heart failure (CHF) and iron deficiency (ID) improves symptoms, functional capacity, and quality of life. We sought to investigate whether these beneficial outcomes are independent of anaemia. METHODS AND

resultsFAIR-HF randomized 459 patients with CHF [NYHA class II or III, LVEF ≤40% (NYHA II) or ≤45% (NYHA III)] and ID to i.v. iron as ferric carboxymaltose (FCM) or placebo in a 2:1 ratio. We analysed the efficacy and safety according to the presence or absence of anaemia (haemoglobin ≤120 g/L) at baseline. Of 459 patients, 232 had anaemia at baseline (51%). The effect of FCM on the primary endpoints of self-reported Patient Global Assessment (PGA) and NYHA class at week 24 was similar in patients with and without anaemia [odds ratio (OR) for improvement, 2.48 vs. 2.60, P = 0.97 for PGA and 1.90 vs. 3.39, P = 0.51 for NYHA). Results were also similar for the secondary endpoints, including PGA and NYHA at weeks 4 and 12, 6 min walk test distance, Kansas City Cardiomyopathy Questionnaire overall score, and European Quality of Life-5 Dimensions Visual Analogue Scale at most time points. Regarding safety, no differences were noticed in the rates of death or first hospitalization between FCM and placebo both in anaemic and in non-anaemic patients.

conclusionsTreatment of ID with FCM in patients with CHF is equally efficacious and shows a similar favourable safety profile irrespective of anaemia. Iron status should be assessed in symptomatic CHF patients both with and without anaemia and treatment of ID should be considered.

Indexed as

Iron DeficienciesAdministration, IntravenousAgedAnemia, Iron-DeficiencyCase-Control StudiesChronic DiseaseDeficiency DiseasesFemaleFerric CompoundsHeart FailureHematinicsHumansMaleMaltoseMiddle AgedQuality of Lifeferric carboxymaltoseFerric CompoundsHematinicsMaltoseAnaemiaFerric carboxymaltoseHeart failureIntravenous ironIron deficiency

Identifiers

PMID23787722
PMCPMC3806282
OpenAlexW2092480503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.